178 related articles for article (PubMed ID: 1697141)
1. Measurement of immunoreactive prothrombin, des-gamma-carboxy prothrombin, and vitamin K in human liver tissues: overproduction of immunoreactive prothrombin in hepatocellular carcinoma.
Ono M; Ohta H; Ohhira M; Sekiya C; Namiki M
Am J Gastroenterol; 1990 Sep; 85(9):1149-54. PubMed ID: 1697141
[TBL] [Abstract][Full Text] [Related]
2. The effects of vitamin K on the generation of des-gamma-carboxy prothrombin (PIVKA-II) in patients with hepatocellular carcinoma.
Sakon M; Monden M; Gotoh M; Kobayashi K; Kanai T; Umeshita K; Endoh W; Mori T
Am J Gastroenterol; 1991 Mar; 86(3):339-45. PubMed ID: 1705389
[TBL] [Abstract][Full Text] [Related]
3. Early diagnosis of hepatocellular carcinoma using a sensitive assay for serum des-gamma-carboxy prothrombin: a prospective study.
Ikoma J; Kaito M; Ishihara T; Nakagawa N; Kamei A; Fujita N; Iwasa M; Tamaki S; Watanabe S; Adachi Y
Hepatogastroenterology; 2002; 49(43):235-8. PubMed ID: 11941963
[TBL] [Abstract][Full Text] [Related]
4. Clinical evaluation of plasma abnormal prothrombin (des-gamma-carboxy prothrombin) in hepatobiliary malignancies and other diseases.
Nakao A; Suzuki Y; Isshiki K; Kimura Y; Takeda S; Kishimoto W; Nonami T; Harada A; Takagi H
Am J Gastroenterol; 1991 Jan; 86(1):62-6. PubMed ID: 1702578
[TBL] [Abstract][Full Text] [Related]
5. Levels of vitamin K, immunoreactive prothrombin, des-gamma-carboxy prothrombin and gamma-glutamyl carboxylase activity in hepatocellular carcinoma tissue.
Yamagata H; Nakanishi T; Furukawa M; Okuda H; Obata H
J Gastroenterol Hepatol; 1995; 10(1):8-13. PubMed ID: 7620113
[TBL] [Abstract][Full Text] [Related]
6. Measurement of immunoreactive prothrombin precursor and vitamin-K-dependent gamma-carboxylation in human hepatocellular carcinoma tissues: decreased carboxylation of prothrombin precursor as a cause of des-gamma-carboxyprothrombin synthesis.
Ono M; Ohta H; Ohhira M; Sekiya C; Namiki M
Tumour Biol; 1990; 11(6):319-26. PubMed ID: 2173855
[TBL] [Abstract][Full Text] [Related]
7. A study about mechanisms of des-gamma-carboxy prothrombin's production in hepatocellular carcinoma.
Bertino G; Ardiri AM; Boemi PM; Ierna D; Interlandi D; Caruso L; Minona E; Trovato MA; Vicari S; Li Destri G; Puleo S
Panminerva Med; 2008 Sep; 50(3):221-6. PubMed ID: 18927526
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of simultaneous determination of alpha-fetoprotein and des-gamma-carboxy prothrombin in hepatocellular carcinoma.
Nakao A; Taniguchi K; Inoue S; Harada A; Nonami T; Watanabe K; Takagi H
Semin Surg Oncol; 1996; 12(3):160-3. PubMed ID: 8727604
[TBL] [Abstract][Full Text] [Related]
9. Measurement of des-gamma-carboxy prothrombin levels in cancer and non-cancer tissue in patients with hepatocellular carcinoma.
Yuan LW; Tang W; Kokudo N; Sugawara Y; Karako H; Hasegawa K; Aoki T; Kyoden Y; Deli G; Li YG; Makuuchi M
Oncol Rep; 2004 Aug; 12(2):269-73. PubMed ID: 15254687
[TBL] [Abstract][Full Text] [Related]
10. Vitamin K2 inhibits the growth of hepatocellular carcinoma via decrease of des-gamma-carboxy prothrombin.
Ma M; Qu XJ; Mu GY; Chen MH; Cheng YN; Kokudo N; Tang W; Cui SX
Chemotherapy; 2009; 55(1):28-35. PubMed ID: 18974646
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of the abnormal vitamin K-dependent gamma-carboxylation process in human hepatocellular carcinomas.
Huisse MG; Leclercq M; Belghiti J; Flejou JF; Suttie JW; Bezeaud A; Stafford DW; Guillin MC
Cancer; 1994 Sep; 74(5):1533-41. PubMed ID: 7520347
[TBL] [Abstract][Full Text] [Related]
12. Clinical evaluation of plasma abnormal prothrombin (PIVKA-II) in patients with hepatocellular carcinoma.
Fujiyama S; Morishita T; Sagara K; Sato T; Motohara K; Matsuda I
Hepatogastroenterology; 1986 Oct; 33(5):201-5. PubMed ID: 2433199
[TBL] [Abstract][Full Text] [Related]
13. The growth inhibitory effects of vitamins K and their actions on gene expression.
Wang Z; Wang M; Finn F; Carr BI
Hepatology; 1995 Sep; 22(3):876-82. PubMed ID: 7657295
[TBL] [Abstract][Full Text] [Related]
14. Isolation and characterization of a hepatoma-associated abnormal (des-gamma-carboxy)prothrombin.
Liebman HA
Cancer Res; 1989 Dec; 49(23):6493-7. PubMed ID: 2555045
[TBL] [Abstract][Full Text] [Related]
15. Production of abnormal prothrombin (des-gamma-carboxy prothrombin) by hepatocellular carcinoma. A clinical and experimental study.
Okuda H; Obata H; Nakanishi T; Furukawa R; Hashimoto E
J Hepatol; 1987 Jun; 4(3):357-63. PubMed ID: 3036940
[TBL] [Abstract][Full Text] [Related]
16. Acarboxy prothrombin (PIVKA II) as a tumour marker for hepatocellular carcinoma and other liver diseases.
Mohamedein A; Yousif-Kadaru AG; Ahmed SA; Saida H; Zaki ZA; Eldin ; Fedail SS
East Afr Med J; 1995 Sep; 72(9):584-7. PubMed ID: 7498046
[TBL] [Abstract][Full Text] [Related]
17. Des-gamma-carboxy prothrombin in cancer and non-cancer liver tissue of patients with hepatocellular carcinoma.
Tang W; Miki K; Kokudo N; Sugawara Y; Imamura H; Minagawa M; Yuan LW; Ohnishi S; Makuuchi M
Int J Oncol; 2003 May; 22(5):969-75. PubMed ID: 12684661
[TBL] [Abstract][Full Text] [Related]
18. [Des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma].
Yamashiki M; Kosaka Y
Rinsho Byori; 1989 Feb; 37(2):118-21. PubMed ID: 2471846
[No Abstract] [Full Text] [Related]
19. Des-gamma-carboxy prothrombin (PIVKA-II) and alpha-fetoprotein-producing IIc-type early gastric cancer.
Kudo M; Takamine Y; Nakamura K; Shirane H; Uchida H; Kasakura S; Kajiwara T; Ibuki Y; Hirasa M; Tomita S
Am J Gastroenterol; 1992 Dec; 87(12):1859-62. PubMed ID: 1280406
[TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics among patients with hepatocellular carcinoma according to the serum levels of alpha-fetoprotein and des-y-carboxy prothrombin.
Dohmen K; Shigematsu H; Irie K; Ishibashi H
Hepatogastroenterology; 2003; 50(54):2072-8. PubMed ID: 14696467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
